ACE and hepatocellular carcinoma: AFP-L3 has a high sensitivity for early-stage HCC 24: reflects the progression and migration of HCC, such as DCP and AFP 25; and can be used to predict the risk of HCC in nonalcoholic fatty liver disease (NAFLD) patients 26.